TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
PMN

ProMIS Neurosciences Inc.

Healthcare · Biotechnology

9.40$ -0.3% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow PMN
Line item 2005 2006 2007 2008 2009 2010 2011 2012 2013 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-4,228.6% -1,164.6% -705.0% -2,246.1% -195.2% -2,537.3% -3,980.2% -3,343.7% -398.2% -5,687.5% -94,534.3% -45,804.0% -1,819,749.1% -506,627.7% -278,255.8% -56,608.8% -281,217.6% – – –
30.8% 11.0% 35.2% 101.2% 13.0% 233.2% 153.4% 101.6% 4.3% 27.6% 247.9% 53.6% 1,404.5% 712.1% 1,005.0% 278.5% 185.2% – – –
– – – 487.9% 81.2% 580.6% 393.4% 145.4% 151.1% 2,014.4% 21,241.4% 5,579.7% 226,303.3% 53,859.7% 26,486.6% 3,091.3% 8,050.4% – – –
– – – – – – – – – – – – 308,231.9% 53,859.7% 26,486.6% 8,460.4% -56,854.9% – – –
78.7% 113.6% -50.0% -131.8% -26.0% 410.7% -114.8% -254.8% -36.0% -32.4% 16,823.9% -2,988.2% 92,999.7% 68,386.9% 50,136.0% -9,508.6% 89,192.5% – – –
257.6% 39.1% 106.3% 50.9% 1.0% 23.9% 9.4% 2.6% 0.6% 0.0% 129,558.7% 0.0% 1.6% 9,040.4% 6,943.5% 36.7% 32.7% – – –
-14,650.4% 1,103.3% 1,103.3% -6.6% 305.5% 560.2% 181.5% 184.7% -0.6% -148.2% -7.6% -1.6% -43.3% -17.3% -7,148.6% 575.1% -32.7% – – –
– – – – – – – – – – – – – – – -9,854.5% – – – –
– – – – – – – – – – – – 2,496,459.0% 724,305.4% 556,303.6% 52,195.1% 0.0% – – –
17,681.9% 176.9% 46.5% 2,071.4% 41.0% 723.1% 2,251.9% 3,530.7% 366.3% 9,010.3% 87,437.5% 53,663.2% 1,967,142.6% 446,084.4% 244,973.5% 153,655.8% 107,222.2% – – –
4,281.9% 289.0% -281.3% -741.0% -27.0% -1,281.0% -2,356.5% -1,573.9% 6.9% 3,174.6% -7,104.3% 7,857.5% 147,349.9% -60,560.6% -40,431.0% 96,935.9% -182,726.8% – – –
-4,385.7% -673.5% -1,270.9% -1,907.9% -335.2% -2,561.2% -4,726.6% -4,052.3% -472.3% -5,687.5% -94,534.3% -45,804.0% -1,819,749.1% -506,627.7% -285,199.4% -56,645.5% -281,250.3% – – –

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?